'5 fu' presentation slideshows

II-III ???????????? ????????????

II-III ???????????? ????????????. ??????? ????????. ???????. ??????. TNM ??????. ????????. ????????????. T 1-2 N 0 M 0 : <10%. T 3-4 N 0 M 0 , T 1 N 1 M 0 : 15-30%. T 3-4 N 1-2 M 0 : 40-50%. TME ????????. ?????. 1980-1996 ??????? : 417 ? ?? : ????????? 5cm ??? : ?? TME ??

1.54k views • 106 slides

Chemotherapy for Metastatic Colon Cancer

Scott Berry Sunnybrook Health Sciences Centre. Chemotherapy for Metastatic Colon Cancer. Where Were We Until 2000?. O. F. HN. O. N H. 5-FU. oxaliplatin. irinotecan. C. H. 3. C. H. O. 2. O. N. N. N. O. C. O. O. N. H. O. C. H. C. H. 2. 3. NH 2. O. C. Pt. O.

1.44k views • 83 slides

Management of Chemo-immunotherapy toxicities

1.19k views • 71 slides

Treating Advanced Colorectal Cancer: 15 minutes, 13 abstracts

Treating Advanced Colorectal Cancer: 15 minutes, 13 abstracts. Richard M Goldberg MD Professor and Chief of Heme/Onc Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill. Topics: Chemotherapy N = 2241. First-line chemotherapy comparisons

825 views • 71 slides

Anti-neoplastic drugs ?????

1.07k views • 63 slides

Treatment of advanced Metastatic Gastric Cancer:

Treatment of advanced Metastatic Gastric Cancer:. Ofer Purim Chief Gastrointestinal Malignancy Service Assuta Samson Hospital Ashdod, Israel. PP-RB-IL-0019. Gastric cancer: a global disease. 4th most common malignant disease ~ 930,000

2.53k views • 56 slides

1.07k views • 52 slides

Ca ????????

870 views • 46 slides

604 views • 46 slides

Axel Grothey Professor of Oncology Mayo Clinic, Rochester, Minnesota, USA

Axel Grothey Professor of Oncology Mayo Clinic, Rochester, Minnesota, USA. Vice Chair and Director of Cancer Treatment of the North Central Cancer Treatment Group (NCCTG) Co-chair of the gastrointestinal program of NCCTG

569 views • 43 slides

Capecitabine: the new standard chemotherapy in advanced gastric cancer?

Werner Scheithauer Professor of Internal Medicine, Cancer Center at the Vienna University Hospital, Austria. Capecitabine: the new standard chemotherapy in advanced gastric cancer?. Werner Scheithauer University Hospital Vienna, Austria. Gastric cancer: a global disease.

665 views • 41 slides

Weijing Sun, MD Associate Professor of Medicine Director of GI Medical Oncology

Gastroesophageal Adenocarcinoma Are We on the Right Track?. Weijing Sun, MD Associate Professor of Medicine Director of GI Medical Oncology Abramson Cancer Center University of Pennsylvania. Abstract 4515:

585 views • 39 slides

Pancreatic cancer

829 views • 38 slides

NDA 21-063

NDA 21-063. Oxaliplatin in combination with 5-FU and leucovorin for first line therapy for colorectal cancer.

439 views • 28 slides

BICC-C Study

BICC-C Study. A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib versus Placebo as First-line Treatment for Patients with Metastatic Colorectal Cancer

530 views • 28 slides

336 views • 17 slides

Xeloda: simplifying the complexity of treatment for metastatic colorectal cancer (MCRC)

Xeloda: simplifying the complexity of treatment for metastatic colorectal cancer (MCRC). Eric Van Cutsem University Hospital Gasthuisberg Leuven, Belgium. Xeloda is an ideal combination partner for cytotoxic and biological agents.

385 views • 16 slides

Case study two: XELIRI

Case study two: XELIRI. Yehuda Patt University of New Mexico Albuquerque, NM, USA. Rationale for combining Xeloda with irinotecan in MCRC. Xeloda generates 5-FU preferentially in tumor and has high single-agent, first-line activity

257 views • 9 slides

Background

FLOX Effect In Subsets Defined by Significant Treatment Interaction. Overall FLOX Treatment Effect. National Surgical Adjuvant Breast and Bowel Project. Male < 70. Female < 70. Group Pts Events FULV 587 222 FLOX 552 188 HR 0.87 (0.71-1.05), P = 0.15.

111 views • 1 slides